The NCI/Cancer Therapy Evaluation Program Project Team carefully evaluated the results of completed and ongoing ATR inhibitor studies, as well as the known pharmacokinetic (PK) data for elimusertib, to establish evidence-based dose schedules for combination regimens. The gene discussed is ATR; the disease is cancer.